Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2013 Jan;15(1):83-4.
doi: 10.1038/aja.2012.133. Epub 2012 Dec 3.

Identification, characterization and targeting of Docetaxel-resistant prostate cancer cells

Tanya I Stoyanova  1 , Andrew S Goldstein
Affiliations
Comment

Identification, characterization and targeting of Docetaxel-resistant prostate cancer cells

Tanya I Stoyanova et al. Asian J Androl. 2013 Jan.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Isolation and characterization of Docetaxel-resistant prostate cancer cells. (a) Cells preferentially surviving Docetaxel treatment express low levels of pan-HLAI-antigens and CK and high levels of active Notch and Hedgehog signaling. (b) Prostate cancer cells with a Docetaxel-resistant phenotype can serve as tumor initiating cells. (c) Docetaxel-resistant prostate cancer cells are dependent on Notch and Hedgehog signaling. CK, cytokeratins.
See this image and copyright information in PMC

Comment on

References

    1. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Prac Urol. 2009;6:76–85. - PMC - PubMed
    1. Amaral TM, Macedo D, Fernandes I, Costa L. Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate Cancer. 2012;2012:327253. - PMC - PubMed
    1. Tsao CK, Small AC, Galsky MD, Oh WK. Overcoming castration resistance in prostate cancer. Curr Opin Urol. 2012;22:167–74. - PubMed
    1. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr, Jones JA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20. - PubMed
    1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12. - PubMed

LinkOut - more resources